- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Researchers on Verge of Breakthrough New Class of Cancer Drugs
Inhibiting a previously undruggable protein holds promise for treatment of numerous types of cancer.
Blocking a specific protein linked with cancer growth may lead to the development of a breakthrough new class of oncology drugs, a recent study found.
The study, published in the current issue of ACS Chemical Biology, evaluated 6 chemical compounds that inhibit the so-called “oncoprotein” HuR, which binds to RNA and promotes tumor growth.
"These are the first reported small-molecule HuR inhibitors that competitively disrupt HuR-RNA binding and release the RNA, thus blocking HuR function as a tumor-promoting protein," corresponding author Liang Xu said in a press release.
Read more at Specialty Pharmacy TImes: http://bit.ly/1aUR8oP
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
